Nadia Solovieff
Harvard University
H-index: 29
North America-United States
Top articles of Nadia Solovieff
Methodology for Good Machine Learning with Multi‐Omics Data
Clinical Pharmacology & Therapeutics
2024/4
Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2− Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA …
Clinical Cancer Research
2024/2/16
Nadia Solovieff
H-Index: 20
Fei Su
H-Index: 4
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials
Annals of Oncology
2023/11/1
Fei Su
H-Index: 4
Nadia Solovieff
H-Index: 20
Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing
Science translational medicine
2023/3/29
Nadia Solovieff
H-Index: 20
Fei Su
H-Index: 4
Abstract PD17-08: Pooled gene expression analysis and association with treatment response in patients with HR+/HER2− advanced breast cancer in the MONALEESA-2,-3, and-7 trials
Cancer Research
2023/3/1
Nadia Solovieff
H-Index: 20
Abstract P5-02-14: Identification of mechanisms of acquired resistance to ribociclib plus endocrine therapy using baseline and end-of-treatment circulating tumor DNA samples in …
Cancer Research
2023/3/1
Nadia Solovieff
H-Index: 20
Multi-omics investigation on the prognostic and predictive factors in metastatic breast cancer using data from Phase III ribociclib clinical trials: A statistical and machine …
medRxiv
2023
Abstract GS2-00: correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2,-3, and-7 studies of ribociclib+ endocrine therapy in patients with HR+ …
Cancer Research
2022/2/15
Nadia Solovieff
H-Index: 20
Abstract P5-13-18: Upregulation of immune response biomarkers by ribociclib plus endocrine therapy (ET) in paired tumor samples from phase I studies
Cancer Research
2022/2/15
Abstract PD2-05: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2-advanced breast cancer (ABC) across the MONALEESA (ML) studies
Cancer Research
2022/2/15
Nadia Solovieff
H-Index: 20
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced …
Clinical Cancer Research
2022/3/1
Clonal hematopoiesis detection in cancer patients using cell free DNA sequencing
bioRxiv
2021/10/29
Nadia Solovieff
H-Index: 20
Fei Su
H-Index: 4
1084P PLATForM: Descriptive analysis from a randomised, phase II study of novel spartalizumab combinations in previously treated unresectable/metastatic melanoma
Annals of Oncology
2021/9/1
Genomic profiling of premenopausal HR+ and HER2–metastatic breast cancer by circulating tumor DNA and association of genetic alterations with therapeutic response to endocrine …
JCO precision oncology
2021/8
Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA phase III studies
Journal of Clinical Oncology
2021/5/5
Nadia Solovieff
H-Index: 20
Fei Su
H-Index: 4
Upregulation of Immune Response Biomarkers by Ribociclib Plus Endocrine Therapy in Paired Tumor Samples From Phase I Studies
San Antonio Breast Cancer Symposium 2021
2021
